Reuters logo
2 个月内
BRIEF-Protalix Biotherapeutics announces FDA approval to operate its current facility as a multi-product facility
2017年6月1日 / 中午11点40分 / 2 个月内

BRIEF-Protalix Biotherapeutics announces FDA approval to operate its current facility as a multi-product facility

1 分钟阅读

June 1 (Reuters) - Protalix Biotherapeutics Inc

* Protalix Biotherapeutics announces FDA approval to operate its current facility as a multi-product facility

* Protalix Biotherapeutics Inc - approval of SNDA allows co to convert its manufacturing facility in Carmiel, Israel, to a multi-product facility

* Protalix Biotherapeutics Inc - supplemental new drug application submitted to U.S. Food and Drug Administration has been approved by FDA

* Protalix Biotherapeutics expects conversion of the facility to multi-product facilitywill allow company to realize potentially significant operational savings

* Protalix Biotherapeutics - "conversion of facilities did not entail substantial additional capital expenditures" Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below